【摘要】：目的:制備水飛薊素腸溶聚乳酸-羥基乙酸共聚物(PLGA)納米粒,并研究其體外釋藥行為。方法:以羥丙基甲基纖維素鄰苯二甲酸酯(HPMCP)為腸溶材料,采用納米沉淀法制備水飛薊素腸溶PLGA納米粒和水飛薊素PLGA納米粒,觀察其形態(tài),檢測(cè)其粒徑、Zeta電位、包封率、載藥量、穩(wěn)定性、體外釋放度(Q)。以粒徑、包封率、載藥量為指標(biāo)篩選水飛薊素腸溶PLGA納米粒中PLGA-HPMCP質(zhì)量比。結(jié)果:PLGA-HPMCP的最佳質(zhì)量比為1∶0.25。所制水飛薊素腸溶PLGA納米粒和水飛薊素PLGA納米粒的粒徑分別為224、193 nm,Zeta電位分別為-37.8、-40.7 m V;包封率分別為(74.7±2.2)%、(71.7±2.5)%,載藥量分別為(5.39±0.24)%、(5.21±0.22)%;4℃下儲(chǔ)存3個(gè)月后的滲漏率分別為0.2%、0.5%;人工胃液中Q_(48h)分別為38.6%、70.5%,人工腸液中Q48 h分別為80.2%、73.5%。結(jié)論:成功制得水飛薊素腸溶PLGA納米粒,其穩(wěn)定性較好,能有效抑制水飛薊素在人工胃液中的釋放。
[Abstract]:Aim: to prepare silymarin enteric poly (lactic acid-glycolic acid) (PLGA) nanoparticles and study their drug release behavior in vitro. Methods: silymarin enteric PLGA nanoparticles and silymarin PLGA nanoparticles were prepared using hydroxypropyl methyl cellulose phthalate (HPMCP) as enteric material. The morphology of silymarin enteric PLGA nanoparticles and silymarin PLGA nanoparticles were observed. Stability, in vitro release of (Q). The mass ratio of PLGA-HPMCP in enteric PLGA nanoparticles of silymarin was screened according to the particle size, encapsulation efficiency and drug load. Results the optimum mass ratio of 1: 0. 25 for 1: PLGA-HPMCP. The silymarin enteric PLGA nanoparticles and silymarin PLGA nanoparticles had 224193 nm,Zeta potential of -37.8 and 40.7 MV respectively, the entrapment efficiency was (74.7 鹵2.2), (71.7 鹵2.5), the drug loading was (5.39 鹵0.24), and the leakage rate of artificial stomach was 0.550 after storage at 4 鈩，

本文編號(hào)：2235607